- Home
- ARQT vs PCRX Comparison
ARQT vs PCRX Comparison
Compare ARQT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- PCRX
- Stock Information
- Founded
- ARQT 2016
- PCRX 2006
- Country
- ARQT United States
- PCRX United States
- Employees
- ARQT N/A
- PCRX N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- PCRX Health Care
- Exchange
- ARQT Nasdaq
- PCRX Nasdaq
- Market Cap
- ARQT 1.1B
- PCRX 1.2B
- IPO Year
- ARQT 2020
- PCRX 2011
- Fundamental
- Price
- ARQT $13.02
- PCRX $25.16
- Analyst Decision
- ARQT Strong Buy
- PCRX Buy
- Analyst Count
- ARQT 6
- PCRX 9
- Target Price
- ARQT $17.00
- PCRX $26.22
- AVG Volume (30 Days)
- ARQT 2.3M
- PCRX 786.1K
- Earning Date
- ARQT 02-25-2025
- PCRX 02-27-2025
- Dividend Yield
- ARQT N/A
- PCRX N/A
- EPS Growth
- ARQT N/A
- PCRX N/A
- EPS
- ARQT N/A
- PCRX N/A
- Revenue
- ARQT $138,708,000.00
- PCRX $694,957,000.00
- Revenue This Year
- ARQT $217.37
- PCRX $5.55
- Revenue Next Year
- ARQT $55.64
- PCRX $5.64
- P/E Ratio
- ARQT N/A
- PCRX N/A
- Revenue Growth
- ARQT 182.84
- PCRX 4.40
- 52 Week Low
- ARQT $6.99
- PCRX $11.16
- 52 Week High
- ARQT $16.20
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- ARQT 50.16
- PCRX 52.48
- Support Level
- ARQT $11.13
- PCRX $25.41
- Resistance Level
- ARQT $13.62
- PCRX $26.89
- Average True Range (ATR)
- ARQT 1.04
- PCRX 1.18
- MACD
- ARQT 0.08
- PCRX -0.36
- Stochastic Oscillator
- ARQT 67.26
- PCRX 4.35
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.